Search results
Showing 3651 to 3700 of 4091 results for patient
In development Reference number: GID-TA11582 Expected publication date: TBC
Discontinued Reference number: GID-TA10965
Discontinued Reference number: GID-TA11252
Discontinued Reference number: GID-TA11339
In development Reference number: GID-TA11366 Expected publication date: TBC
In development Reference number: GID-TA11884 Expected publication date: TBC
Discontinued Reference number: GID-TA11034
Discontinued Reference number: GID-TA11033
In development Reference number: GID-TA11586 Expected publication date: TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Discontinued Reference number: GID-TA11411
Discontinued Reference number: GID-TA11035
This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition by improving the way it’s planned and carried out. It covers both health and social care.
Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]
Discontinued Reference number: GID-TA10963
Discontinued Reference number: GID-TA11180
In development Reference number: GID-TA11690 Expected publication date: TBC
Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]
Discontinued Reference number: GID-TAG398
Discontinued Reference number: GID-TA10502
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]
Discontinued Reference number: GID-TA10958
In development Reference number: GID-TA11165 Expected publication date: TBC
Discontinued Reference number: GID-TAG456
In development Reference number: GID-TA11486 Expected publication date: TBC
Discontinued Reference number: GID-TA11476
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]
Discontinued Reference number: GID-TA11009
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
In development Reference number: GID-TA11253 Expected publication date: TBC
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]
Discontinued Reference number: GID-TA11108
In development Reference number: GID-TA11567 Expected publication date: TBC
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
Discontinued Reference number: GID-TA11357
In development Reference number: GID-TA11400 Expected publication date: TBC
In development Reference number: GID-TA11663 Expected publication date: TBC
In development Reference number: GID-TA11511 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)
Discontinued Reference number: GID-TA10803
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
Discontinued Reference number: GID-TA11244
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]
Discontinued Reference number: GID-TA11020
Discontinued Reference number: GID-TA11204
In development Reference number: GID-TA11401 Expected publication date: TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]
In development Reference number: GID-TA11265 Expected publication date: TBC
In development Reference number: GID-TA11021 Expected publication date: TBC
In development Reference number: GID-TA11089 Expected publication date: TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
In development Reference number: GID-TA11368 Expected publication date: TBC
Botulinum toxin type A for preventing episodic migraine [ID6450]
In development Reference number: GID-TA11505 Expected publication date: TBC
In development Reference number: GID-TA11299 Expected publication date: TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
In development Reference number: GID-TA11022 Expected publication date: TBC
In development Reference number: GID-TA11278 Expected publication date: TBC
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
Discontinued Reference number: GID-TA10480
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]
In development Reference number: GID-TA11044 Expected publication date: TBC
In development Reference number: GID-TA11607 Expected publication date: 13 January 2027
In development Reference number: GID-TA11166 Expected publication date: TBC
In development Reference number: GID-TA11093 Expected publication date: TBC
Discontinued Reference number: GID-TA11026